MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

Search

Exelixis Inc

Closed

SectorHealthcare

34.3 -6.28

Overview

Share price change

24h

Current

Min

34.3

Max

34.9

Key metrics

By Trading Economics

Income

140M

Sales

27M

567M

P/E

Sector Avg

20.676

63.778

EPS

0.55

Profit margin

24.678

Employees

1,147

EBITDA

171M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+9.57% upside

Dividends

By Dow Jones

Next Earnings

29 Apr 2025

Market Stats

By TradingEconomics

Market Cap

718M

10B

Previous open

40.58

Previous close

34.3

News Sentiment

By Acuity

50%

50%

156 / 386 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Exelixis Inc Chart

Past performance is not a reliable indicator of future results.

Related News

4 Apr 2025, 22:38 UTC

Hot Stocks

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

5 Apr 2025, 15:00 UTC

Top News

U.S.-Stock Funds Have a Quarter to Forget -- Journal Report

5 Apr 2025, 15:00 UTC

Top News

The Complicated Relationship Between Consumer Sentiment and Stocks -- Journal Report

5 Apr 2025, 14:38 UTC

Top News

Trump's Trade Broadside Puts Chinese Economy Under Heavy Pressure -- WSJ

5 Apr 2025, 09:30 UTC

Earnings

Elon Musk's Mr. Fix-It Takes Center Stage During a Really Bad Week -- WSJ

5 Apr 2025, 01:00 UTC

Acquisitions, Mergers, Takeovers

How BlackRock's Larry Fink Won Over Donald Trump -- WSJ

5 Apr 2025, 01:00 UTC

Acquisitions, Mergers, Takeovers

How BlackRock's Larry Fink Won Over Donald Trump -- WSJ -2-

4 Apr 2025, 21:53 UTC

Market Talk

Maxeon's Supply Chain Move at Critical Time for Solar Panel Cos -- Market Talk

4 Apr 2025, 21:44 UTC

Top News
Acquisitions, Mergers, Takeovers

Trump Grants 75-Day Extension to Reach TikTok Deal -- 3rd Update

4 Apr 2025, 21:00 UTC

Top News

Americans Were Souring on Trump's Economic Plans Even Before Tariff Bloodbath -- WSJ

4 Apr 2025, 20:52 UTC

Market Talk

Peloton Likely to Escape Tariffs Unscathed -- Market Talk

4 Apr 2025, 20:52 UTC

Top News

Trump Can Cut Teacher-Training Programs For Now, Supreme Court Says -- WSJ

4 Apr 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

4 Apr 2025, 20:48 UTC

Top News

The Score: Nike, Apple, Stellantis and More Stocks That Defined the Week -- WSJ

4 Apr 2025, 20:45 UTC

Top News

Hiring Defied Expectations in March, With 228,000 New Jobs -- 6th Update

4 Apr 2025, 20:32 UTC

Top News

Dow Tumbles 2,000 Points, Bonds Rally After China Retaliates Against Trump Tariffs -- WSJ

4 Apr 2025, 20:21 UTC

Top News

China Hits Back at Trump With Sweeping Tariffs on All U.S. Goods -- Update

4 Apr 2025, 20:00 UTC

Top News

Republicans March Ahead on Trump's Tax Cuts as Tariffs Kick In -- WSJ

4 Apr 2025, 19:51 UTC

Market Talk

Dollar Recovers While Recession Fears Grip Wall Street -- Market Talk

4 Apr 2025, 19:37 UTC

Top News

Trump's Team is Getting the Bond Rally It Wanted. But for the Wrong Reasons. -- WSJ

4 Apr 2025, 19:32 UTC

Market Talk

Oil Selloff Continues as China Responds to U.S. Tariffs -- Market Talk

4 Apr 2025, 19:28 UTC

Top News

U.S. Stocks Fall Further After China Retaliates Against Trump Tariffs -- Update

4 Apr 2025, 19:15 UTC

Market Talk

Costco Gold, Membership Fees Could Help Cushion from Tariff Costs -- Market Talk

4 Apr 2025, 19:12 UTC

Top News

Powell Warns of Higher Prices, Weaker Growth After Tariff Plan -- 3rd Update

4 Apr 2025, 19:11 UTC

Market Talk

U.S. Natural Gas Falls as Global Selloff Continues -- Market Talk

4 Apr 2025, 19:09 UTC

Market Talk

Mexican Stocks, Peso Tumble as Global Rout Continues -- Market Talk

4 Apr 2025, 19:09 UTC

Top News

Trump Grants 75-Day Extension to Reach TikTok Deal -- Second Update

4 Apr 2025, 19:00 UTC

Market Talk

Fed Has Limited Options to Counter Tariffs -- Market Talk

4 Apr 2025, 18:53 UTC

Market Talk

Brace for Trump's Tariff Order to Remain in Place for Extended Period -- Market Talk

4 Apr 2025, 18:51 UTC

Market Talk

Morgan Stanley Analysts Outline Paths to Recession -- Market Talk

Peer Comparison

Price change

Exelixis Inc Forecast

Price Target

By TipRanks

9.57% upside

12 Months Forecast

Average 37.88 USD  9.57%

High 45 USD

Low 29 USD

Based on 17 Wall Street analysts offering 12 month price targets forExelixis Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

17 ratings

10

Buy

7

Hold

0

Sell

Technical Score

By Trading Central

N/A / 36.96Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Weak Bullish Evidence

Sentiment

By Acuity

156 / 386 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Exelixis Inc

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.